CBX4 and neoplasm: To evaluate whether CBX4 and its upstream regulator miR424 affect sorafenib resistance in HCC in vivo, we examined tumour growth with variant genetically altered cells by constantly treating mice with sorafenib (10 mg/kg/day) via oral administration for 9 days.